Lipocine (NASDAQ:LPCN – Get Free Report) posted its earnings results on Thursday. The specialty pharmaceutical company reported $0.33 EPS for the quarter, topping the consensus estimate of ($0.26) by $0.59, Zacks reports.
Lipocine Price Performance
Shares of LPCN stock opened at $3.21 on Thursday. The stock has a market capitalization of $17.17 million, a price-to-earnings ratio of -4.22 and a beta of 1.42. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79. The company’s fifty day simple moving average is $4.01 and its two-hundred day simple moving average is $4.53.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Lipocine in a research note on Thursday, March 6th. They set a “hold” rating on the stock.
Lipocine Company Profile
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Stories
- Five stocks we like better than Lipocine
- What is the Hang Seng index?
- Is a Bottom Finally Forming in Rocket Lab Stock?
- Insider Trades May Not Tell You What You Think
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- Profitably Trade Stocks at 52-Week Highs
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
